Thursday, April 15, 2010

Abstract: Systane after cat surgery

The effect of preservative-free HP-Guar on dry eye after phacoemulsification: a flow cytometric study.
Eye (Lond). 2010 Mar 19. [Epub ahead of print]
Sánchez MA, Arriola-Villalobos P, Torralbo-Jiménez P, Girón N, de la Heras B, Herrero Vanrell R, Alvarez-Barrientos A, Benítez-Del-Castillo JM.
Department of Ophthalmology, Hospital Clínico San Carlos, Madrid, Spain.

Purpose
To assess the effect of hydroxypropyl (HP)-Guar added to regular post-phacoemulsification treatment in dry eye signs and symptoms, and its influence on the expression of various inflammatory markers by flow cytometry (FCM) in impression cytology specimens.
Methods
This prospective, interventional, single-centre study included 48 eyes of 48 patients with age-related cataract. After phacoemulsification, patients were randomised to the usual treatment group (UT), with 21 patients who received tobramycin and dexamethasone eye drops (Tobradex, Alcon Cusí, Spain), and the HP-Guar group, with 27 patients who received the UT plus preservative-free artificial tears (Systane UD, Alcon Cusí, Spain). Corneal and conjunctival staining with fluorescein and lissamine green, tear film break-up time (TBUT), Schirmer's I test with anaesthesia (Jones test), tear clearance, and ocular surface disease index (OSDI) were assessed preoperatively and 1 month after surgery. Besides, conjunctival impression cytology was performed in order to investigate inflammatory markers (CD3, CD11b, and HLA-DR) using FCM.
Results
HP-Guar group shows statistical better results compared with the UT group in TBUT (6.4+/-0.7 vs9+/-2.5, P=0.0004), OSDI (11.5+/-8.2 vs3.3+/-2.5, P=0.0002), ocular symptoms subscale (7.3+/-6.1 vs1.7+/-1.8, P=0.0004), vision-related function subscale (2.2+/-1.8 vs0.4+/-0.6, P=0.0002), CD3 (2.5+/-1.4 vs1.1+/-1.1, P=0.011), and HLA-DR (6.8+/-4.5 vs1.8+/-1.7, P=0.0002).
Conclusion
The addition of HP-Guar to regular treatment after cataract surgery reduces ocular surface inflammation and dry eye signs and symptoms.

No comments: